The p53 circuit board
Open accessThe DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
The p53 tumor suppressor is embedded in a large gene network controlling diverse cellular and organismal phenotypes. Multiple signaling pathways converge onto p53 activation, mostly by relieving the inhibitory effects of its repressors, MDM2 and MDM4. In turn, signals originating from increased p53 activity diverge into distinct effector pathways to deliver a specific cellular response to the activating stimuli. Much attention has been devoted to dissecting how the various input pathways trigger p53 activation and how the activity of the p53 protein itself can be modulated by a plethora of co-factors and post-translational modifications. In this review we will focus instead on the multiple configurations of the effector pathways. We will discuss how p53-generated signals are transmitted, amplified, resisted and eventually integrated by downstream gene circuits operating at the transcriptional, post-transcriptional and post-translational level. We will also discuss how context-dependent variations in these gene circuits define the cellular response to p53 activation and how they may impact the clinical efficacy of p53-based targeted therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661 · cited 3×
“Nutlin-3 was shown to bind MDM2with nanomolar efficiency, activate p53 and suppress tumor growth, all without inducing the cytotoxic side effects associated with traditional chemotherapeutics [193].”
InfluentialTumor suppressor p53 is a direct transcriptional activator of the human bax gene
Toshiyuki, M., & Reed, J. C. (1995) · Cell · doi:10.1016/0092-8674(95)90412-3 · Cited by 4,063 · cited 1×
“ing components of the intrinsic (mitochondrial) pathway such as PUMA, NOXA, BID, BAX andAPAF1 [72,73,75,119–121], aswell asmembers of the extrinsic (death receptor) pathway such as FAS, DR4 and DR5/Killer [122–124].”
The landscape of somatic copy-number alteration across human cancers
Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017
Regulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312 · cited 1×
“With the discovery of MDM2, a repressor of p53 [18–20],”
Blinded by the Light: The Growing Complexity of p53
Vousden, K. H., & Prives, C. (2009) · Cell · doi:10.1016/j.cell.2009.04.037 · Cited by 3,163 · cited 1×
“We refer those readers interested in the p53 molecule to many excellent p53-centered reviews [27–31].”
Momand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113
Kastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., & Fornace, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90593-2 · Cited by 3,047
A microRNA component of the p53 tumour suppressor network
He, L., He, X., Lim, L. P., de Stanchina, E., Xuan, Z., Liang, Y., Xue, W., Zender, L., Magnus, J., Ridzon, D., et al. (2007) · Nature · doi:10.1038/nature05939 · Cited by 2,692
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473 · cited 1×
“The validity of p53 as a therapeutic target has been elegantly proven in animal models where specific activation of p53 in tumors leads to their demise via apoptosis or senescence [187,188].”
PUMA, a Novel Proapoptotic Gene, Is Induced by p53
Nakano, K., & Vousden, K. H. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00214-3 · Cited by 2,315
Mice Lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control
Deng, C., Zhang, P., Wade Harper, J., Elledge, S. J., & Leder, P. (1995) · Cell · doi:10.1016/0092-8674(95)90039-x · Cited by 2,113
Noxa, a BH3-Only Member of the Bcl-2 Family and Candidate Mediator of p53-Induced Apoptosis
Oda, E., Ohki, R., Murasawa, H., Nemoto, J., Shibue, T., Yamashita, T., Tokino, T., Taniguchi, T., & Tanaka, †. N. (2000) · Science · doi:10.1126/science.288.5468.1053 · Cited by 2,112
p63 is a p53 homologue required for limb and epidermal morphogenesis
Mills, A. A., Zheng, B., Wang, X.-J., Vogel, H., Roop, D. R., & Bradley, A. (1999) · Nature · doi:10.1038/19531 · Cited by 1,988
The p53 proto-oncogene can act as a suppressor of transformation
Finlay, C. A., Hinds, P. W., & Levine, A. J. (1989) · Cell · doi:10.1016/0092-8674(89)90045-7 · Cited by 1,987
The first 30 years of p53: growing ever more complex.
Levine, A. J., & Oren, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2723 · Cited by 1,967 · cited 1×
“We refer those readers interested in the p53 molecule to many excellent p53-centered reviews [27–31].”
Transcriptional control of human p53-regulated genes
Riley, T., Sontag, E., Chen, P., & Levine, A. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2395 · Cited by 1,921
Restoration of p53 function leads to tumour regression in vivo
Ventura, A., Kirsch, D. G., McLaughlin, M. E., Tuveson, D. A., Grimm, J., Lintault, L., Newman, J., Reczek, E. E., Weissleder, R., & Jacks, T. (2007) · Nature · doi:10.1038/nature05541 · Cited by 1,820 · cited 1×
“The validity of p53 as a therapeutic target has been elegantly proven in animal models where specific activation of p53 in tumors leads to their demise via apoptosis or senescence [187,188].”
Peng, C.-Y., Graves, P. R., Thoma, R. S., Wu, Z., Shaw, A. S., & Piwnica-Worms, H. (1997) · Science · doi:10.1126/science.277.5331.1501 · Cited by 1,341 · cited 1×
“14-3-3σ is a direct transcriptional target of p53 that binds to the mitotic phosphatase CDC25 and sequesters it in the cytoplasm, thus preventing it from activating CDK1-cyclin B complexes [63,64].”
p53- and Drug-Induced Apoptotic Responses Mediated by BH3-Only Proteins Puma and Noxa
Villunger, A., Michalak, E. M., Coultas, L., Müllauer, F., Böck, G., Ausserlechner, M. J., Adams, J. M., & Strasser, A. (2003) · Science · doi:10.1126/science.1090072 · Cited by 1,327
Is a p53-Regulated Inhibitor of G2/M Progression
Hermeking, H., Lengauer, C., Polyak, K., He, T.-C., Zhang, L., Thiagalingam, S., Kinzler, K. W., & Vogelstein, B. (1997) · Molecular Cell · doi:10.1016/s1097-2765(00)80002-7 · Cited by 1,251
Radiation-induced cell cycle arrest compromised by p21 deficiency
Brugarolas, J., Chandrasekaran, C., Gordon, J. I., Beach, D., Jacks, T., & Hannon, G. J. (1995) · Nature · doi:10.1038/377552a0 · Cited by 1,242 · cited 1×
“its loss does not completely abrogate the ability of p53 to halt proliferation, which demonstrates the existence of redundant and cooperative pathways [102,103].”
Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound
Bykov, V. J. N., Issaeva, N., Shilov, A., Hultcrantz, M., Pugacheva, E., Chumakov, P., Bergman, J., Wiman, K. G., & Selivanova, G. (2002) · Nature Medicine · doi:10.1038/nm0302-282 · Cited by 1,067 · cited 1×
“A subsequent screen for compounds to reactivate mutant p53 identified PRIMA-1 (p53 reactivation and induction of massive apoptosis) [192].”
Rivlin, N., Brosh, R., Oren, M., & Rotter, V. (2011) · Genes & Cancer · doi:10.1177/1947601911408889 · Cited by 1,033
14-3-3σ is required to prevent mitotic catastrophe after DNA damage
Chan, T. A., Hermeking, H., Lengauer, C., Kinzler, K. W., & Vogelstein, B. (1999) · Nature · doi:10.1038/44188 · Cited by 895 · cited 1×
“p21 and 14-3-3σ work coordinately to enforce cell cycle arrest in response to various DNA damaging agents and protect from apoptosis [65,66].”
Awakening guardian angels: drugging the p53 pathway
Brown, C. J., Lain, S., Verma, C. S., Fersht, A. R., & Lane, D. P. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2763 · Cited by 881 · cited 1×
“each type of therapy [190].”
p53 Activates the CD95 (APO-1/Fas) Gene in Response to DNA Damage by Anticancer Drugs
Müller, M., Wilder, S., Bannasch, D., Israeli, D., Lehlbach, K., Li-Weber, M., Friedman, S. L., Galle, P. R., Stremmel, W., Oren, M., et al. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.11.2033 · Cited by 878 · cited 1×
“ing components of the intrinsic (mitochondrial) pathway such as PUMA, NOXA, BID, BAX andAPAF1 [72,73,75,119–121], aswell asmembers of the extrinsic (death receptor) pathway such as FAS, DR4 and DR5/Killer [122–124].”
Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy
Tovar, C., Rosinski, J., Filipovic, Z., Higgins, B., Kolinsky, K., Hilton, H., Zhao, X., Vu, B. T., Qing, W., Packman, K., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507493103 · Cited by 708
Shangary, S., & Wang, S. (2009) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.113006.094723 · Cited by 623
Stepwise Activation of BAX and BAK by tBID, BIM, and PUMA Initiates Mitochondrial Apoptosis
Kim, H., Tu, H.-C., Ren, D., Takeuchi, O., Jeffers, J. R., Zambetti, G. P., Hsieh, J. J.-D., & Cheng, E. H.-Y. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.09.030 · Cited by 600 · cited 1×
“tein required for permeabilization of the outer mitochondrial membrane [76].”
Apaf-1 is a transcriptional target for E2F and p53
Moroni, M. C., Hickman, E. S., Denchi, E. L., Caprara, G., Colli, E., Cecconi, F., Müller, H., & Helin, K. (2001) · Nature Cell Biology · doi:10.1038/35078527 · Cited by 593 · cited 1×
“ing components of the intrinsic (mitochondrial) pathway such as PUMA, NOXA, BID, BAX andAPAF1 [72,73,75,119–121], aswell asmembers of the extrinsic (death receptor) pathway such as FAS, DR4 and DR5/Killer [122–124].”
Wild-type p53 activates transcription in vitro
Farmer, G., Bargonetti, J., Zhu, H., Friedman, P., Prywes, R., & Prives, C. (1992) · Nature · doi:10.1038/358083a0 · Cited by 579 · cited 1×
“[13–17].”
Concurrent versus individual binding of HuR and AUF1 to common labile target mRNAs
Lal, A., Mazan‐Mamczarz, K., Kawai, T., Yang, X., Martindale, J. L., & Gorospe, M. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600305 · Cited by 461 · cited 1×
“demonstrated that while AUF1 and HuR can bind to adjacent sites in the p21 3′ UTR to promote nuclear export, in the absence of HuR, AUF1 shifts its binding position to promote destabilization of the mRNA [47].”
BID regulation by p53 contributes to chemosensitivity
Sax, J. K., Fei, P., Murphy, M. E., Bernhard, E., Korsmeyer, S. J., & El-Deiry, W. S. (2002) · Nature Cell Biology · doi:10.1038/ncb866 · Cited by 420 · cited 1×
“ing components of the intrinsic (mitochondrial) pathway such as PUMA, NOXA, BID, BAX andAPAF1 [72,73,75,119–121], aswell asmembers of the extrinsic (death receptor) pathway such as FAS, DR4 and DR5/Killer [122–124].”
p73 Induces apoptosis via PUMA transactivation and Bax mitochondrial translocation
Melino, G., Bernassola, F., Ranalli, M., Yee, K., Zong, W. X., Corazzari, M., Knight, R. A., Green, D. R., Thompson, C., & Vousden, K. H. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m307469200 · Cited by 368
Espinosa, J. M., Verdun, R. E., & Emerson, B. M. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00359-9 · Cited by 256 · cited 4×
“specific p53 cofactors such as histone acetyl-transferases and subunits of the core Mediator complex [131–134].”
InfluentialSelf-citationMdm2 is critically and continuously required to suppress lethal p53 activity in vivo
Ringshausen, I., O'Shea, C. C., Finch, A. J., Swigart, L. B., & Evan, G. I. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.010 · Cited by 256
The CRL4Cdt2 ubiquitin ligase targets the degradation of p21Cip1 to control replication licensing
Kim, Y., Starostina, N. G., & Kipreos, E. T. (2008) · Genes & Development · doi:10.1101/gad.1703708 · Cited by 240 · cited 1×
“Ubiquitin-mediated degradation of p21 occurs at different phases of the cell cycle, directed by different E3 ligases including SCF, APC/C and CRL4 [56–58].”
p53 Upregulates Death Receptor 4 Expression through an Intronic p53 Binding Site
Liu, X., Yue, P., Khuri, F. R., & Sun, S.-Y. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1195 · Cited by 184 · cited 1×
“ing components of the intrinsic (mitochondrial) pathway such as PUMA, NOXA, BID, BAX andAPAF1 [72,73,75,119–121], aswell asmembers of the extrinsic (death receptor) pathway such as FAS, DR4 and DR5/Killer [122–124].”
Regulation of p21WAF1/CIP1 Stability by WISp39, a Hsp90 Binding TPR Protein
Jascur, T., Brickner, H., Salles-Passador, I., Barbier, V., El Khissiin, A., Smith, B., Fotedar, R., & Fotedar, A. (2005) · Molecular Cell · doi:10.1016/j.molcel.2004.11.049 · Cited by 145
Perp Is a Mediator of p53-Dependent Apoptosis in Diverse Cell Types
Ihrie, R. A., Reczek, E., Horner, J. S., Khachatrian, L., Sage, J., Jacks, T., & Attardi, L. D. (2003) · Current Biology · doi:10.1016/j.cub.2003.10.055 · Cited by 118 · cited 1×
“PERP is a membrane protein whose overexpression is sufficient to cause cell death in various cell types [137,138].”
p21 does not protect cancer cells from apoptosis induced by nongenotoxic p53 activation
Xia, M., Knezevic, D., & Vassilev, L. T. (2011) · Oncogene · doi:10.1038/onc.2010.413 · Cited by 64
Vaseva, A. V., Yallowitz, A. R., Marchenko, N. D., Xu, S., & Moll, U. M. (2011) · Cell Death & Disease · doi:10.1038/cddis.2011.39 · Cited by 55
BH3 activation blocks Hdmx suppression of apoptosis and cooperates with Nutlin to induce cell death
Wade, M., Rodewald, L. W., Espinosa, J. M., & Wahl, G. M. (2008) · Cell Cycle · doi:10.4161/cc.7.13.6072 · Cited by 48
Self-citation
Cited by
Kastenhuber, E. R., & Lowe, S. W. (2017) · Cell · doi:10.1016/j.cell.2017.08.028 · Cited by 1,906
The ATM protein kinase: regulating the cellular response to genotoxic stress, and more
Shiloh, Y., & Ziv, Y. (2013) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3546 · Cited by 1,649
P53 in survival, death and metabolic health: a lifeguard with a licence to kill.
Kruiswijk, F., Labuschagne, C. F., & Vousden, K. H. (2015) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm4007 · Cited by 1,080
ATM and ATR as therapeutic targets in cancer
Weber, A. M., & Ryan, A. J. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.12.001 · Cited by 635
Anjum, S., Hashim, M., Malik, S. A., Khan, M., Lorenzo, J. M., Abbasi, B. H., & Hano, C. (2021) · Cancers · doi:10.3390/cancers13184570 · Cited by 575
Metadata
- Authors
- Sullivan, K. D., Gallant-Behm, C. L., Henry, R. E., Fraikin, J.-L., & Espinosa, J. M.
- Venue
- Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
- Publisher
- Elsevier BV
- Published
- 2012-04
- Volume
- 1825
- Issue
- 2
- Pages
- 229-244
- ISSN
- 0304-419X (ISSN-L)
- OpenAlex
- W1987788885
- Cited by
- 91
- References
- 43
- FWCI
- 7.24
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.